Advanced Filters
noise

Richmond, Virginia Clinical Trials

A listing of Richmond, Virginia clinical trials actively recruiting patient volunteers.

Found 295 clinical trials
V Vanessa B Sheppard, PhD

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening tool. In this study, the investigators aim to evaluate the efficacy of a culturally targeted …

18 years of age Female Phase N/A
I In Gino, MD

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via …

18 years of age All Phase 2/3
K Kendra Rowe

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

18 years of age All Phase 1
G Gaurav Gupta, MD

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+Rkidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in …

18 years of age All Phase 3
M Massey Heme Malig Team

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

18 years of age All Phase 2
C Courtney Breiner

A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders

The purpose of this proposal is to launch the first trial of a single-session intervention (SSI) specifically for the prevention of eating disorders (EDs).

18 - 22 years of age All Phase N/A
E Edmund Acevedo, PhD

Psychobiological Responses Following Exercise and Brain Stimulation

Anxiety disorders are the most common mental health diagnosis in the US; 19.1% of U.S. adults (23.4% for females and 14.3% for males). In addition, the Global Burden of Disease study (2010) found that anxiety disorders were the sixth leading cause of disability (years of life lived with disability). These …

18 - 50 years of age All Phase N/A
J Jessica Brady

Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds

The goal of this study is to look at clinical outcomes when Cohealyx Collagen Matrix is used to treat full thickness wounds after surgical excision in patients that require a skin graft to heal their wounds. The main question it aims to answer is how long does it take for …

years of age All Phase N/A
M Michelle Sclafani

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.

60 years of age All Phase N/A
A Anthony Sabulski, MD

A Study of Emapalumab for Pediatric Aplastic Anemia

The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options.

- 25 years of age All Phase 2

Simplify language using AI